Indaptus Therapeutics is trading 16.71% up now at $2.16, with no confirmed company-specific catalyst identified for the September 9 move.

  • It rose 51.64% to $1.85 on September 8.
  • Recent coverage highlights an earlier 59-million-share resale filing and a September 4 board-member resignation.
  • Available market coverage reports no recent news explaining the current rally.